Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 23, 2024, by Cidara Therapeutics, Inc. It reports on material definitive agreements entered into, including a Technology Transfer and License Agreement with Janssen Pharmaceuticals and a Securities Purchase Agreement involving a private placement of preferred stock. The document also mentions board changes related to the transaction. The content focuses on announcements of agreements and transactions rather than providing comprehensive financial statements or detailed financial analysis. Form 8-K filings are current reports used to announce major events and are classified under Regulatory Filings (RNS) as they do not fit into other specific report categories like Annual Report or Capital/Financing Update directly, since this is a formal SEC filing reporting multiple material events. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-24 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text details the entry into a material definitive agreement involving the sale of assets and related agreements, including an asset purchase agreement, novation agreement, and license amendment. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not a transcript, proxy, or governance document. The document is a regulatory filing announcing a significant corporate event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not merely an announcement of a report but a substantive filing about a material event.
2024-04-24 English
CIDARA THERAPEUTICS, INC. FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cidara Therapeutics, Inc. on April 22, 2024. Form S-8 is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. The document includes details about the registration of additional shares under the company's 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan. It contains legal exhibits, consents, and signatures but does not include financial statements or performance data. This type of filing is related to share issue/capital changes specifically for employee benefit plans. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (9182 characters) and content confirm it is the registration statement itself, not just an announcement or certification.
2024-04-22 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 22, 2024. It includes a press release reporting financial results for the fourth quarter and year ended December 31, 2023, but the actual financial results are contained in the attached press release (Exhibit 99.1), not in the body of this filing. The document also details a reverse stock split and amendments to the certificate of incorporation. The document is primarily an announcement of events and financial results via press release, not the full financial report itself. The length is 7497 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for SEC Form 8-K filings that announce events and results but do not contain full financial statements or detailed analysis themselves.
2024-04-22 English
CIDARA THERAPEUTICS, INC. 2023 FORM 10-K
Annual Report FY 2023
2024-04-22 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2024, by Cidara Therapeutics, Inc. It reports a non-reliance on previously issued financial statements due to restatements related to indirect tax liabilities. The document discusses the Audit Committee's determination, the involvement of the independent auditor Ernst & Young LLP, and the plan to restate prior financial statements in the upcoming Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The content focuses on audit-related matters, restatement of prior financials, and internal control weaknesses, which are typical of an Audit Report or Information filing rather than the full Annual Report itself. The document is not the full annual report but a current report disclosing audit-related issues and restatement plans. Therefore, the appropriate classification is Audit Report / Information (AR).
2024-04-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.